Published in Clin Chem on January 17, 2008
Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. Endocrine (2008) 1.30
The cancer secretome: a reservoir of biomarkers. J Transl Med (2008) 1.16
Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy. BMC Gastroenterol (2009) 1.12
Characterization of proteins secreted by pancreatic cancer cells with anticancer drug treatment in vitro. Oncol Rep (2012) 0.84
Circulating matrix metalloproteinase-7: an early or metastatic marker for renal cell carcinoma? Clin Chem (2008) 0.78
Serum and biliary MMP-9 and TIMP-1 concentrations in the diagnosis of cholangiocarcinoma. Int J Clin Exp Med (2015) 0.77
Serum Matrix Metalloproteinase-7 is an independent prognostic biomarker in advanced bladder cancer. Clin Transl Med (2014) 0.77
A Pilot Study Evaluating Serum MMP7 as a Preoperative Prognostic Marker for Pancreatic Ductal Adenocarcinoma Patients. J Gastrointest Surg (2016) 0.76
Matrix Metalloproteinases-7 and Kidney Fibrosis. Front Physiol (2017) 0.75
EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol (2010) 8.21
Renal cell carcinoma guideline. Eur Urol (2007) 3.42
Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol (2005) 3.15
Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol (2007) 2.92
Update on the medical treatment of metastatic renal cell carcinoma. Eur Urol (2008) 2.80
Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol (2008) 2.45
Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol (2009) 2.41
Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol (2010) 2.38
Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol (2008) 2.37
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int (2008) 2.35
Collecting duct renal cell carcinoma: a matched analysis of 41 cases. Eur Urol (2007) 2.30
The conserved transcriptome in human and rodent male gametogenesis. Proc Natl Acad Sci U S A (2007) 2.30
Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol (2006) 2.15
Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer (2005) 2.15
Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol (2007) 2.09
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.99
Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol (2007) 1.96
Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol (2009) 1.92
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol (2007) 1.90
Prognostic value of thrombocytosis in renal cell carcinoma. J Urol (2006) 1.87
Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. Eur Urol (2011) 1.87
Urinary collecting system invasion is an independent prognostic factor of organ confined renal cell carcinoma. J Urol (2009) 1.83
A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol (2008) 1.77
Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol (2012) 1.75
Tumor size is a determinant of the rate of stage T1 renal cell cancer synchronous metastasis. J Urol (2009) 1.73
Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. J Urol (2007) 1.67
Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation. J Urol (2011) 1.63
A proposal for reclassification of the Fuhrman grading system in patients with clear cell renal cell carcinoma. Eur Urol (2009) 1.61
Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur Urol (2010) 1.60
Laparoscopic partial nephrectomy with clamping of the renal parenchyma: initial experience. Eur Urol (2007) 1.60
Nephron-sparing surgery is equally effective to radical nephrectomy for T1BN0M0 renal cell carcinoma: a population-based assessment. Urology (2009) 1.58
Renal cell carcinoma (RCC) arising in native kidneys of dialyzed and transplant patients: are they different entities? BJU Int (2012) 1.56
Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study. Urology (2008) 1.55
Thirty-day mortality after nephrectomy: clinical implications for informed consent. Eur Urol (2008) 1.53
Platelet count and preoperative haemoglobin do not significantly increase the performance of established predictors of renal cell carcinoma-specific mortality. Eur Urol (2007) 1.51
Radical versus partial nephrectomy: effect on overall and noncancer mortality. Cancer (2009) 1.51
Raman spectroscopy: a novel experimental approach to evaluating renal tumours. Eur Urol (2010) 1.49
Competing-risks analysis in patients with T1 squamous cell carcinoma of the penis. BJU Int (2012) 1.48
Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol (2006) 1.48
Sex, age, and surgeon decision on nephron-sparing surgery are independent predictors of renal masses with benign histologic findings--a multicenter survey. Urology (2010) 1.46
Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study. J Clin Oncol (2011) 1.45
Optical spectroscopy techniques can accurately distinguish benign and malignant renal tumours. BJU Int (2012) 1.45
A contemporary population-based assessment of the rate of lymph node dissection for penile carcinoma. Ann Surg Oncol (2010) 1.43
[Kidney tumors]. Prog Urol (2007) 1.43
[Molecular pathways of tumour angiogenesis and new targeted therapeutic approaches in renal cancer]. Prog Urol (2005) 1.43
C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer (2007) 1.43
Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer (2008) 1.43
Oncologic outcomes and survival in pT0 tumors after radical cystectomy in patients without neoadjuvant chemotherapy: results from a large multicentre collaborative study. Ann Surg Oncol (2011) 1.42
Detailed analysis of morbidity following nephrectomy for renal cell carcinoma in octogenarians. J Urol (2012) 1.42
Tyrosine-kinase inhibitors in the treatment of muscle invasive bladder cancer and hormone refractory prostate cancer. Arch Esp Urol (2010) 1.41
Overall mortality after radical nephrectomy in patients aged over 80 years with renal cancer: a retrospective study on preoperative prognostic factors. Int J Urol (2012) 1.41
The prognostic value of erythrocyte polyamine in the post-nephrectomy stratification of renal cell carcinoma specific mortality. J Urol (2009) 1.40
Thrombocytopenia resulting from mutations in filamin A can be expressed as an isolated syndrome. Blood (2011) 1.37
Synaptic multiprotein complexes associated with 5-HT(2C) receptors: a proteomic approach. EMBO J (2002) 1.35
Relationship between age at diagnosis and clinicopathologic features of renal cell carcinoma. Eur Urol (2006) 1.27
Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology (2008) 1.26
Quantitative phosphoproteomics reveals a cluster of tyrosine kinases that mediates SRC invasive activity in advanced colon carcinoma cells. Cancer Res (2009) 1.25
Squamous cell carcinoma arising in a hepatic forgut cyst. Pathol Res Pract (2002) 1.23
Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin Cancer Res (2009) 1.23
Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol (2012) 1.21
Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol (2009) 1.21
Depletion of one, six, twelve or twenty major blood proteins before proteomic analysis: the more the better? J Proteomics (2009) 1.20
A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study. BJU Int (2008) 1.20
Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience. BJU Int (2007) 1.19
Proteomic analysis of astrocytic secretion in the mouse. Comparison with the cerebrospinal fluid proteome. J Biol Chem (2003) 1.18
KRAS mutation detection in paired frozen and Formalin-Fixed Paraffin-Embedded (FFPE) colorectal cancer tissues. Int J Mol Sci (2011) 1.17
Renal tumors: diagnostic and prognostic biomarkers. Am J Surg Pathol (2013) 1.17
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology (2011) 1.15
Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles. Breast Cancer Res (2011) 1.14
Blood-feeding and immunogenic Aedes aegypti saliva proteins. Proteomics (2010) 1.14
Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. J Pathol (2012) 1.14
Prognostic factors and selection for clinical studies of patients with kidney cancer. Crit Rev Oncol Hematol (2007) 1.13
Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol (2007) 1.13
Prognostic ability of simplified nuclear grading of renal cell carcinoma. Cancer (2007) 1.11
Re: clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review. J Natl Cancer Inst (2012) 1.08
Characteristics of the coexistence of melanoma and renal cell carcinoma. Cancer (2010) 1.08
Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma. Eur Urol (2003) 1.08
Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur Urol (2009) 1.07
The changing evolution of renal tumours: a single center experience over a two-decade period. Eur Urol (2004) 1.06
Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval. J Urol (2007) 1.06
Renal cell carcinoma in young adults: incidence, disease outcome and review of the literature. Arch Esp Urol (2002) 1.03
Age at diagnosis is a determinant factor of renal cell carcinoma-specific survival in patients treated with nephrectomy. Can Urol Assoc J (2008) 1.03
[Management of acute prostatitis, based on a series of 100 cases]. Prog Urol (2005) 1.03
Conditional survival predictions after nephrectomy for renal cell carcinoma. J Urol (2009) 1.02
HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer. Cancer Treat Rev (2011) 1.02
The cancer-testis gene, NY-ESO-1, is expressed in normal fetal and adult testes and in spermatocytic seminomas and testicular carcinoma in situ. Lab Invest (2002) 1.02
Transperitoneal laparoscopic nephrectomy for autosomal dominant polycystic kidney disease. JSLS (2013) 1.01